Prognostic Gene Expression Profiling Testing and Sentinel Lymph Node Biopsy Risk Prediction

The presentation focuses on prognostic gene expression profiling (GEP) testing and its implications for sentinel lymph node biopsy (SLNB) in melanoma patients. The presenter discusses three commercial GEP tests: the Melogenics test, the Decision DX Melanoma test, and the Merlin test, which analyze gene expressions to predict the biological behavior and potential metastasis of melanoma lesions. The significance of GEP results is highlighted, particularly in situations where they conflict with traditional staging predictions, posing challenges in management decisions. The presenter emphasizes that while GEP tests may enhance prognostic accuracy, their clinical utility remains uncertain due to a lack of robust evidence demonstrating positive patient outcomes based on GEP results. Current guidelines do not endorse these tests due to insufficient data on their impact on management strategies. The talk concludes by stressing the need for further research and clinical trials to clarify the roles of GEP in guiding treatment and reducing unnecessary procedures, potentially affording better patient outcomes and streamlining management.